What is the market size of digital biomarkers?

As of 2027 the market size of digital biomarkers is valued at USD 6.95 billion.

How is the digital biomarkers industry projected to perform over the next decade?

Digital Biomarkers Market size stood at USD 5.9 billion in 2026 and is predicted to grow at a 21.19% CAGR from 2027 to 2036, crossing USD 40.32 billion by 2036.

How are wearable devices and smartphones transforming data collection in the digital biomarkers market?

Widespread use of wearables and smartphones enables continuous collection of physiological and behavioral data, allowing longitudinal health monitoring that supports both research and care delivery through scalable, real-world data generation.

How is decentralized clinical research influencing adoption of digital biomarkers?

Decentralized trials and remote monitoring are increasing demand for validated digital endpoints that reduce site dependence, improve patient retention, and integrate sensor-based data capture with compliant platforms for modern clinical study design.

Why are wearable devices the largest type segment in the digital biomarkers market?

Wearable devices captured a 41.98% share in 2026 because they enable continuous passive monitoring, providing consistent physiological and behavioral data for patient monitoring, research, and digital health applications.

Why are payers the fastest-growing end-use segment in the digital biomarkers market?

Payers are adopting digital biomarkers fastest because objective real-world health data helps improve outcome tracking, care management, coverage decisions, and healthcare utilization across insured populations.

Why is North America the leading digital biomarkers market?

North America captured 61.32% of the market in 2026, supported by its mature digital health ecosystem, rapid integration into clinical research, and widespread adoption of connected patient monitoring solutions.

What is accelerating digital biomarkers market growth in Asia Pacific?

Asia Pacific is projected to grow at a 24.2% CAGR, driven by expanding digital health adoption, increasing use of connected devices, and broader implementation of remote patient monitoring across healthcare systems.

Which organizations are considered leaders in the digital biomarkers landscape?

Prominent players in the digital biomarkers market include AliveCor, Inc. (United States), Koneksa Health Inc. (United States), ActiGraph LLC (United States), Altoida, Inc. (United States), Empatica Inc. (United States), Huma Therapeutics Limited (United Kingdom), Clario (United States), Sonde Health, Inc. (United States), Kinsa Inc. (United States), Biogen Inc. (United States).